Controlled inhalation of aerosolised therapeutics

Expert Opinion on Drug Delivery

Volumn 2, Issue 4, 2005, Pages 763-767

  Bennett, William D ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aerosol delivery; Aerosol deposition; Breathing patterns

Indexed keywords

AKITA; ALPHA 1 ANTITRYPSIN; BETA INTERFERON; CALCITONIN; DEOXYRIBONUCLEASE; DNA; GLUTATHIONE; GROWTH HORMONE; INSULIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AEROSOL; ARTICLE; BIOTECHNOLOGY; BREATHING PATTERN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DNA TRANSFER; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; EQUIPMENT DESIGN; GENE THERAPY; INDIVIDUALIZATION; LUNG PARENCHYMA; LUNG VENTILATION; MEDICAL NEBULIZER; PARTICLE SIZE; PATIENT COMPLIANCE; SEDIMENTATION; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; HUMANS; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE;

EID: 22844446862     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.4.763     Document Type: Article

References (27)

1. Drug Delivery to the Lung. H Bisgaard, C O'Callaghan, GC Smaldone (Eds), Marcel Dekker, Inc, New York, NY, USA (2002) c2002.
2. NEWHOUSE MT: Tennis anyone? The lungs as a new court for systemic therapy. Can. Med. Assoc. J. (1999) 161(10):1287-1288.
3. HERSHEY AE, KURZMAN ID, FORREST LJ et al.: Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin. Cancer Res. (1999) 5(9):2653-2659.
4. 1-protease inhibitor using commercial inhalation devices. Eur. Respir. J. (2003) 22:263-267.
5. BENNETT WD, BROWN JS, ZEMAN KL, HU SC, SCHEUCH G, SOMMERER K: Targeting delivery of aerosols to different lung regions. J. Aerosol Med. (2002) 15:179-188.
6. STAHLHOFEN W, RUDOLF G, JAMES AC: Intercomparison of experimental regional aerosol deposition data. J. Aerosol Med. (1989) 2(3):285-308.
7. PAVIA D, THOMSON ML: The fractional deposition of inhaled 2 and 5 micron particles in the alveolar and tracheobronchial regions of the healthy human lung. Ann. Occup. Hygiene (1976) 19:109.
8. PAVIA D, THOMSON ML, CLARKE SW, SHANNON HS: Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax (1977) 32(2):194-197.
9. BROWN JS, ZEMAN KL, BENNETT WD: Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J. Aerosol Med. (2001) 14:443-454.
10. BROWN JS, BENNETT WD: Deposition of coarse particles in cystic fibrosis: model predictions versus experimental results. J. Aerosol Med. (2004) 17(3):239-248.
11. BROWN JS, BENNETT WD: Optimizing the regional deposition of aerosols in cystic fibrosis. J. Aerosol Med. (2003) 16:204 (Abstract).
12. HEYDER J, GEBRART J, STAHLHOFEN W, STUCK B: Biological variability of particle deposition in the human respiratory tract during controlled and spontaneous mouth-breathing. Ann. Occup. Hyg. (1982) 26:137-147.
13. BRAND P, FRIEMEL I, MEYER T, SCHULZ J, HAUSSINGER K: Total deposition of therapeutic particles during spontaneous and controlled inhalations. J. Pharm. Sci. (2000) 89:724-731.
14. BENNETT WD, ZEMAN KL, KIM CS: Variability of fine particle deposition in healthy adults: effect of age and gender. Am. J. Resp. Crit. Care Med. (1996) 153(5):1641-1647.
15. DENYER J, NIKANDER K, SMITH NJ: Adaptive aerosol delivery (AAD®) technology. Expert Opin. Drug Deliv. (2004) 1(1):165-176.
16. SCHEUCH G, MEYER T, MULLINGER B et al.: Controlled inhalation improves peripheral lung deposition. J. Aerosol Sci. (2001) 14:388.
17. GRIESE M, RAMAKERS J, KRASSELT A et al.: Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am. J. Respir. Crit. Care Med. (2004) 169:822-828.
18. KORST RJ, MCELVANEY NG, CHU CS et al.: Gene therapy for the respiratory manifestations of cystic fibrosis. Am. J. Respir. Crit. Care Med. (1995) 151:S75-S87.
19. STAHLHOFEN W, GEBHART J, RUDOLF G, SCHEUCH G: Measurement of lung clearance with pulses of radioactively labelled particles. J. Aerosol Sci. (1986) 17:333-338.
20. BENNETT WD, SCHEUCH G, ZEMAN KL et al.: Bronchial airway deposition and retention of particles in inhaled boli: effect of anatomic dead space. J. Appl. Physiol. (1998) 85:685-694.
21. ALEXIS NE, HU SC, ZEMAN K, ALTER T, BENNETT WD: Induced sputum derives from the central airways: confirmation using a radiolabeled aerosol bolus delivery technique. Am. J. Resp. Crit. Care Med. (2001) 164:1964-1970.
22. ANDERSON M, PHILIPSON K, SVARTENGREN M, CAMNER P: Human deposition and clearance of 6 μm particles inhaled with an extremely low flow rate. Exp. Lung Res. (1995) 21:187-195.
23. HAEUSSERMAN S, BRAND P, SCHULTE M et al.: Optimization of lung deposition in patients with cystic fibrosis. Am. J. Resp. Crit. Care Med. (2004) 169(7):A391.
24. MEYER T, BRAND P, HERPICH C, SCHEUCH G, WEBER N: Controlled inhalation of beta2-sympaticomimetica after bronchial provocation. Pneumologie (2003) 57(11):644-647.
25. GELLER D, ROSENFELD M, WALTZ DA, WILMOTT RW: Efficiency of Pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest (2003) 123:28-36.
26. GELLER D, THIPPHAWONG J, OTULANA B et al.: Bolus inhalation of rhDNase with AERx system in subjects with cystic fibrosis. J. Aerosol Med. (2003) 16:175-182.
27. BYRNE NM, KEAVEY PM, PERRY JD, GOULD FK, SPENCER DA: Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch. Dis. Child. (2003) 88:715-718.